Answers are grounded in this paper and cite their sources.
Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
No takes yet. Share an insight, caveat, or question.
King et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: